CytoSorbents to Report First Quarter 2024 Operating and Financial Results
April 26, 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
April 17, 2024 07:00 ET
|
CytoSorbents
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
March 14, 2024 16:39 ET
|
CytoSorbents
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
March 06, 2024 07:00 ET
|
CytoSorbents
PRINCETON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
February 08, 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
December 28, 2023 07:00 ET
|
CytoSorbents
CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
December 13, 2023 09:15 ET
|
CytoSorbents
CytoSorbents Strengthens Balance Sheet with $10.3M Registered Direct Offering. Insiders invest $435,000
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
November 09, 2023 16:15 ET
|
CytoSorbents
PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
August 01, 2023 16:15 ET
|
CytoSorbents
Q2 2023 Total Revenue was $9.4 million, an 11% increase from $8.5 million in Q2 2022. Product sales rose 10% to $8.1 million vs $7.3 million in Q2 2022. Product gross margins grew 700 basis points...
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
July 07, 2023 07:07 ET
|
CytoSorbents
PRINCETON, N.J., July 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...